RareResearch.AI
← Back to atlas

R629Q

Category 4 — Stable Fold, Function DisruptedConflictingTransmembrane · predictedEditorial
ArginineGlutamine at position 629 · Connecting loop · WFS1 (Wolframin)

Arg→Gln p629 loop AM=0.09 ddg=-0.63 pLDDT=60. ClinVar Conflicting evidence. Atlas mechanism: see structural analysis.

Interactive 3D Structure

Wild-type reference
Wild-type R629 — hydrogen bond to S626
Fullscreen ↗
DynaMut2 mutant · R629Q
Mutant Q629 — polar contact contact to S631 lost
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

1 lost0 gained7 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondS626S626Preserved
Hydrogen bondM632M632Preserved
Polar contactS626S626Preserved
Polar contactL627L627Preserved
Polar contactS631S631Preserved
Polar contactM632M632Preserved
Van der WaalsL627L627Preserved
Van der WaalsS631Lost

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.63kcal/mol
Destabilising — mild
AlphaMissense
0.092
LBen
AlphaFold pLDDT
60
model confidence
Schema
Cat 4
Category 4 — Stable Fold, Function Disrupted
ΔΔG confidence: Low confidence · Transmembrane
  • transmembrane position; predictor benchmarked on soluble proteins
  • pLDDT 59.97 below 70

This variant sits in the transmembrane band. The stability value was computed with a predictor benchmarked on water-soluble proteins. Published benchmarks of ddG predictors on membrane proteins report correlation below 0.4. Treat the magnitude as unreliable and the sign as weak evidence only.

The underlying AlphaFold model has pLDDT below 70 at this position, so the structure the stability calculation was run on is itself uncertain.

Do not rank this value against a variant from a different region on ΔΔG alone.

Clinical Evidence

ClinVar classificationConflicting classifications of pathogenicity
Review statuscriteria provided, conflicting classifications
Associated conditions(no specific conditions catalogued)
InheritanceConflicting ClinVar classifications.
Population frequency (gnomAD v4)Ultra-rare · AF 0.0030%
cDNA changec.1886G>A
ClinVar accessionVCV000045443
Last evaluated2025/06/12 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Conflicting classifications of pathogenicity for WFS1-related diabetes (autosomal dominant); Hearing loss, inheritance unstated (inheritance not specified); Nonsyndromic hearing loss (DFNA6/14/38) (autosomal dominant, OMIM 600965); Wolfram-like syndrome (autosomal dominant, OMIM 614296); Cataract 41 (autosomal dominant, OMIM 116400); Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). These are two clinically distinct disease families: classic Wolfram syndrome requires two affected copies, while the dominant WFS1-related disorders do not. One label covers both, and it does not tell you which applies to a given person.

  • WFS1-related diabetesautosomal dominantsubmitted as: Monogenic diabetes; Type 2 diabetes mellitus
  • Hearing loss, inheritance unstatedinheritance not specifiedsubmitted as: Rare genetic deafness
  • Nonsyndromic hearing loss (DFNA6/14/38)autosomal dominant · OMIM 600965submitted as: Autosomal dominant nonsyndromic hearing loss 6
  • Wolfram-like syndromeautosomal dominant · OMIM 614296submitted as: Wolfram-like syndrome
  • Cataract 41autosomal dominant · OMIM 116400submitted as: Cataract 41
  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1; Wolfram syndrome 1
  • Submitters conflict on this classification (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ conflicting classifications. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.0030% · 49 / 1,614,086 alleles
Homozygotes
0
Highest-frequency population
East Asian · AF 0.0089%

Highest in East Asian: AF 0.0089% (4 of 44,864 alleles), 2.9x the global figure. The global AF describes the general population, not the at-risk group.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
East Asian0.0089%4 / 44,8640~1 in 5610
Remaining individuals0.0080%5 / 62,5060~1 in 6250
African / African American0.0067%5 / 75,0680~1 in 7510
European (non-Finnish)0.0029%34 / 1,180,0420~1 in 17350
Finnish · under-sampled0.0016%1 / 63,9020

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Structural Context

Position analysis: THR628 (2.5 Å — same R629 microregion as R629W), SER630 (2.5 Å), SER626 (3.8 Å). Same position as R629W (AM under-call sister). The Atlas's neighbor extraction surfaces this variant's contacts.

Amino-acid chemistry
charge loss, amide preserved
Position in the protein
Connecting loop

Druggability Assessment

Cat 3/4 AM under-call — see structural prose. AlphaMissense below threshold (AM under-call class) but mechanism is structurally clear from neighbor analysis. Therapeutic strategy: site-directed at the contacts identified above.

Why this matters

R629W + R629Q sister variants.
Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the R629Q PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download R629Q PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.

UniProt Domain Annotation

Chain1890 · Wolframin
Natural variant629629 · in WFS1; dbSNP:rs71530910